Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Добезилат кальция: возможности терапии хронической венозной патологии
Добезилат кальция: возможности терапии хронической венозной патологии
Стойко Ю.М., Гудымович В.Г. Добезилат кальция: возможности терапии хронической венозной патологии. Consilium Medicum. 2017; 19 (7.1. Хирургия): 71–74.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзорной статье, посвященной флеботропной терапии в лечении пациентов с хронической венозной недостаточностью нижних конечностей, рассмотрен один из препаратов данной группы – добезилат кальция. Анализ отечественной и зарубежной литературы свидетельствует об эффективности использования его у пациентов данной категории, что подтверждается рядом международных исследований и включением препарата в Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Механизм действия, обеспечивающий противоотечный, противовоспалительный, антитромботический эффекты, позволяет использовать его не только во флебологии. Мультинаправленное действие добезилата кальция позволяет применять его как ангиопротектор у пациентов с диабетической ретинопатией и нефропатией.
Ключевые слова: хронические заболевания вен нижних конечностей, флеботропные препараты, добезилат кальция.
Key words: chronic venous disease of the lower extremities, phlebotropics, calcium dobesilate.
Ключевые слова: хронические заболевания вен нижних конечностей, флеботропные препараты, добезилат кальция.
________________________________________________
Key words: chronic venous disease of the lower extremities, phlebotropics, calcium dobesilate.
Полный текст
Список литературы
1. Клиническая флебология. Под ред. Ю.Л.Шевченко, Ю.М.Стойко. М.: ДПК Пресс, 2016. / Klinicheskaia flebologiia. Pod red. Iu.L.Shevchenko, Iu.M.Stoiko. M.: DPK Press, 2016. [in Russian]
2. Совещание экспертов. Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен, основанные на принципах доказательной медицины. Рабочие материалы. М., 2008. / Soveshchanie ekspertov. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskikh zabolevanii ven, osnovannye na printsipakh dokazatel'noi meditsiny. Rabochie materialy. M., 2008. [in Russian]
3. Rabe E, Guex JJ, Puskas A et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31 (2): 105–15.
4. Nicolaides A, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33 (2): 126–39.
5. Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4 (4): 221–32.
6. Mestres P, Rodriguez L, Erill S, Laport J. Modification by calcium dobesilate of histamine effects on capillary ultra-structure. Experientia 1975; 31: 826–9.
7. Zabel-Langhennig R, Kulle M. Capillary fragility in diabetics and its modification by calcium dobesilate. Z Gesamte Inn Med 1983; 38: 633–6.
8. Van Bijsterveld OP, Janssen PT. The effect of calcium dobe-silate on albumin leakage of the conjunctival vessels. Curr Eve Res 1981; 1: 425–30.
9. Allain H, Ramelet AA, Polard E, Bentué-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004; 27: 649–60.
10. Demirtas S, Caliskan A, Guclu O et al. Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis? Med Sci Monit Basic Res 2013; 19: 253–7.
11. Alda O, Valero MS, Pereboom D et al. In vitro calcium dobesilate on oxidative/inflammatory stress in hunan varicosae veins. Phlebology 2011; 26 (8): 332–7.
12. Angulo J, Peiró C, Romacho T et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol 2011; 667: 153–9.
13. Brunet J, Farine JC, Garay RP, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998; 12: 205–12.
14. Piller NB. The lymphagogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology 1988; 21: 124–7.
15. Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology 2008; 59 (3): 352–6.
16. Ciapponi A, Laffaire E, Roqué M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004; 55 (2): 147–54.
17. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2016; 4: CD003229.
18. Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология. 2013; 7 (2): 2–48. / Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskikh zabolevanii ven. Flebologiia. 2013; 7 (2): 2–48. [in Russian]
19. Cai T, Wu XY, Zhang XQ et al. Calcium Dobesilate Prevents Diabetic Kidney Disease by Decreasing Bim and Inhibiting Apoptosis of Renal Proximal Tubular Epithelial Cells. DNA Cell Biol 2017; 36 (4): 249–55.
20. Rabe EL, Jaeger KA, Bulitta M, Pannier F. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology 2016; 26 (4): 162–8.
2. Soveshchanie ekspertov. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskikh zabolevanii ven, osnovannye na printsipakh dokazatel'noi meditsiny. Rabochie materialy. M., 2008. [in Russian]
3. Rabe E, Guex JJ, Puskas A et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31 (2): 105–15.
4. Nicolaides A, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33 (2): 126–39.
5. Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4 (4): 221–32.
6. Mestres P, Rodriguez L, Erill S, Laport J. Modification by calcium dobesilate of histamine effects on capillary ultra-structure. Experientia 1975; 31: 826–9.
7. Zabel-Langhennig R, Kulle M. Capillary fragility in diabetics and its modification by calcium dobesilate. Z Gesamte Inn Med 1983; 38: 633–6.
8. Van Bijsterveld OP, Janssen PT. The effect of calcium dobe-silate on albumin leakage of the conjunctival vessels. Curr Eve Res 1981; 1: 425–30.
9. Allain H, Ramelet AA, Polard E, Bentué-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004; 27: 649–60.
10. Demirtas S, Caliskan A, Guclu O et al. Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis? Med Sci Monit Basic Res 2013; 19: 253–7.
11. Alda O, Valero MS, Pereboom D et al. In vitro calcium dobesilate on oxidative/inflammatory stress in hunan varicosae veins. Phlebology 2011; 26 (8): 332–7.
12. Angulo J, Peiró C, Romacho T et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol 2011; 667: 153–9.
13. Brunet J, Farine JC, Garay RP, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998; 12: 205–12.
14. Piller NB. The lymphagogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology 1988; 21: 124–7.
15. Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology 2008; 59 (3): 352–6.
16. Ciapponi A, Laffaire E, Roqué M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004; 55 (2): 147–54.
17. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2016; 4: CD003229.
18. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskikh zabolevanii ven. Flebologiia. 2013; 7 (2): 2–48. [in Russian]
19. Cai T, Wu XY, Zhang XQ et al. Calcium Dobesilate Prevents Diabetic Kidney Disease by Decreasing Bim and Inhibiting Apoptosis of Renal Proximal Tubular Epithelial Cells. DNA Cell Biol 2017; 36 (4): 249–55.
20. Rabe EL, Jaeger KA, Bulitta M, Pannier F. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology 2016; 26 (4): 162–8.
2. Совещание экспертов. Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен, основанные на принципах доказательной медицины. Рабочие материалы. М., 2008. / Soveshchanie ekspertov. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskikh zabolevanii ven, osnovannye na printsipakh dokazatel'noi meditsiny. Rabochie materialy. M., 2008. [in Russian]
3. Rabe E, Guex JJ, Puskas A et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31 (2): 105–15.
4. Nicolaides A, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33 (2): 126–39.
5. Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4 (4): 221–32.
6. Mestres P, Rodriguez L, Erill S, Laport J. Modification by calcium dobesilate of histamine effects on capillary ultra-structure. Experientia 1975; 31: 826–9.
7. Zabel-Langhennig R, Kulle M. Capillary fragility in diabetics and its modification by calcium dobesilate. Z Gesamte Inn Med 1983; 38: 633–6.
8. Van Bijsterveld OP, Janssen PT. The effect of calcium dobe-silate on albumin leakage of the conjunctival vessels. Curr Eve Res 1981; 1: 425–30.
9. Allain H, Ramelet AA, Polard E, Bentué-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004; 27: 649–60.
10. Demirtas S, Caliskan A, Guclu O et al. Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis? Med Sci Monit Basic Res 2013; 19: 253–7.
11. Alda O, Valero MS, Pereboom D et al. In vitro calcium dobesilate on oxidative/inflammatory stress in hunan varicosae veins. Phlebology 2011; 26 (8): 332–7.
12. Angulo J, Peiró C, Romacho T et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol 2011; 667: 153–9.
13. Brunet J, Farine JC, Garay RP, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998; 12: 205–12.
14. Piller NB. The lymphagogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology 1988; 21: 124–7.
15. Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology 2008; 59 (3): 352–6.
16. Ciapponi A, Laffaire E, Roqué M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004; 55 (2): 147–54.
17. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2016; 4: CD003229.
18. Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология. 2013; 7 (2): 2–48. / Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskikh zabolevanii ven. Flebologiia. 2013; 7 (2): 2–48. [in Russian]
19. Cai T, Wu XY, Zhang XQ et al. Calcium Dobesilate Prevents Diabetic Kidney Disease by Decreasing Bim and Inhibiting Apoptosis of Renal Proximal Tubular Epithelial Cells. DNA Cell Biol 2017; 36 (4): 249–55.
20. Rabe EL, Jaeger KA, Bulitta M, Pannier F. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology 2016; 26 (4): 162–8.
________________________________________________
2. Soveshchanie ekspertov. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskikh zabolevanii ven, osnovannye na printsipakh dokazatel'noi meditsiny. Rabochie materialy. M., 2008. [in Russian]
3. Rabe E, Guex JJ, Puskas A et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31 (2): 105–15.
4. Nicolaides A, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33 (2): 126–39.
5. Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4 (4): 221–32.
6. Mestres P, Rodriguez L, Erill S, Laport J. Modification by calcium dobesilate of histamine effects on capillary ultra-structure. Experientia 1975; 31: 826–9.
7. Zabel-Langhennig R, Kulle M. Capillary fragility in diabetics and its modification by calcium dobesilate. Z Gesamte Inn Med 1983; 38: 633–6.
8. Van Bijsterveld OP, Janssen PT. The effect of calcium dobe-silate on albumin leakage of the conjunctival vessels. Curr Eve Res 1981; 1: 425–30.
9. Allain H, Ramelet AA, Polard E, Bentué-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004; 27: 649–60.
10. Demirtas S, Caliskan A, Guclu O et al. Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis? Med Sci Monit Basic Res 2013; 19: 253–7.
11. Alda O, Valero MS, Pereboom D et al. In vitro calcium dobesilate on oxidative/inflammatory stress in hunan varicosae veins. Phlebology 2011; 26 (8): 332–7.
12. Angulo J, Peiró C, Romacho T et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol 2011; 667: 153–9.
13. Brunet J, Farine JC, Garay RP, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998; 12: 205–12.
14. Piller NB. The lymphagogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology 1988; 21: 124–7.
15. Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology 2008; 59 (3): 352–6.
16. Ciapponi A, Laffaire E, Roqué M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004; 55 (2): 147–54.
17. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2016; 4: CD003229.
18. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskikh zabolevanii ven. Flebologiia. 2013; 7 (2): 2–48. [in Russian]
19. Cai T, Wu XY, Zhang XQ et al. Calcium Dobesilate Prevents Diabetic Kidney Disease by Decreasing Bim and Inhibiting Apoptosis of Renal Proximal Tubular Epithelial Cells. DNA Cell Biol 2017; 36 (4): 249–55.
20. Rabe EL, Jaeger KA, Bulitta M, Pannier F. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology 2016; 26 (4): 162–8.
Авторы
Ю.М.Стойко, В.Г.Гудымович*
ФГБУ «Национальный медико-хирургический центр им. Н.И.Пирогова» Минздрава России. 105203, Россия, Москва, ул. Нижняя Первомайская, д. 70
*gudvic@mail.ru
N.I.Pirogov National Medical and Surgical Center of the Ministry of Health of the Russian Federation. 105203, Russian Federation, Moscow, ul. Nizhniaia
Pervomaiskaia, d. 70
*gudvic@mail.ru
ФГБУ «Национальный медико-хирургический центр им. Н.И.Пирогова» Минздрава России. 105203, Россия, Москва, ул. Нижняя Первомайская, д. 70
*gudvic@mail.ru
________________________________________________
N.I.Pirogov National Medical and Surgical Center of the Ministry of Health of the Russian Federation. 105203, Russian Federation, Moscow, ul. Nizhniaia
Pervomaiskaia, d. 70
*gudvic@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.